How to Invest in Anthropic Stock Before the IPO in 2026

On June 1, Anthropic confidentially filed an S-1 with the SEC. Four days earlier it had closed a $65 billion funding round that valued the company at $965 billion. That’s not a typo — the maker of Claude is now worth more than Bank of America, more than Netflix, and for the first time, more than OpenAI, which sits around $852 billion after its March raise.

If you’ve been searching how to invest in Anthropic stock since that filing dropped, you’re not alone. The problem is that most of what’s written about it is either a thinly veiled ad for a pre-IPO platform or a vague “you can’t, sorry” shrug. The real answer is somewhere in between, and it depends almost entirely on whether you’re an accredited investor.

Let me walk through what’s actually possible right now, what it costs, and whether any of it is a good idea at a near-trillion-dollar price tag.

What just happened, in plain terms

A confidential S-1 is not an IPO. It’s a draft registration statement filed privately with the SEC so the company and regulators can go back and forth before anything becomes public. Anthropic hasn’t set a share count, a price range, a ticker, an exchange, or a date. Multiple outlets are pointing at an October 2026 listing window, but that’s reporting, not a commitment.

What we do know is concrete enough. The $65 billion Series H closed on May 28 at a $965 billion post-money valuation — more than 2.5x where Anthropic stood just three months earlier. The company says its run-rate revenue crossed $47 billion. Amazon owns roughly 21% and Alphabet about 15%, stakes that are about to look very smart on paper. Amazon already booked a $16.8 billion pre-tax gain tied to its Anthropic position in its March quarter.

So the company is real, the revenue is real, and the IPO machinery has started turning. None of that tells you whether buying in makes sense. Hold that thought.

Can you actually buy Anthropic stock right now?

Here’s the honest split. If you’re an accredited investor — broadly, $200k+ income ($300k joint) or $1M net worth excluding your home — you have a few real routes to buy shares before the IPO. If you’re not, you can’t buy the stock directly, but you can get indirect exposure through a couple of funds that hold it.

And there’s a catch that trips people up: Anthropic itself has to approve most share transfers. The company has historically kept a tight grip on its cap table and doesn’t allow direct fund investments or open secondary transfers at will. So even when a marketplace shows you a listing, the deal can stall or fall through at the approval stage. Treat any “available” share count as tentative until it clears.

The accredited-investor routes

Secondary marketplaces are where existing shareholders — early employees, ex-employees, seed investors — sell their shares to outside buyers. Three names dominate for Anthropic.

Hiive lists Anthropic shares and, as of early June, was showing a reference price north of $1,300 a share. Minimums typically run $25,000 to $50,000. Hiive’s pitch is transparency — it shows live bids and asks rather than burying pricing behind a sales call, which I appreciate.

EquityZen tends to be the most accessible of the three, with minimums that can start around $10,000 depending on how the deal is structured. It often pools investors into a fund that holds the shares rather than transferring stock to you directly, which matters for fees and for how you eventually exit.

Forge Global sits at the higher end, generally $50,000 to $100,000 minimums. It’s been in the pre-IPO game a long time and has deep institutional plumbing, but you’ll feel the white-glove pricing.

A few things to know before you wire money anywhere. Secondary shares usually carry a markup over the last primary round, so you may be paying a premium on top of an already steep valuation. Fees range from roughly 3% to 5% per transaction depending on platform and structure. And there’s typically a lockup — after the IPO, you often can’t sell for 90 to 180 days, which means you’re exposed to whatever the stock does in its volatile first months with no exit.

When the same share is listed on more than one platform, compare. Pricing and availability genuinely vary, and the spread can be wider than the fees.

The routes anyone can use

No accreditation? Two funds give you a slice of Anthropic, and they take very different approaches.

The Fundrise Innovation Fund lists on the NYSE under the ticker VCX after a direct listing in March 2026. Its biggest holding is Anthropic at around 20.7% of the portfolio, followed by Databricks (17.7%), OpenAI (9.9%), Anduril, Ramp, and SpaceX. So buying VCX is a fairly concentrated bet on private AI, with Anthropic as the centerpiece.

The big asterisk: because it now trades on an exchange, its price floats on supply and demand. Reports have flagged VCX changing hands at a steep premium to its net asset value — by one account, several times NAV. Paying 3x or 4x what the underlying holdings are worth is a fast way to lose money even if Anthropic does fine. Check the premium-to-NAV before you buy, every time.

ARK Venture Fund (ARKVX) is the other door. Minimum initial investment is $500, which is why it gets cited so often as the everyman option. It holds Anthropic alongside SpaceX, OpenAI, Epic Games, Databricks, Discord, and Shield AI. The trade-off is that Anthropic is a smaller slice of a broader basket, and ARKVX is an interval fund — you can buy in regularly, but you can only redeem during scheduled quarterly windows, and only up to a capped amount. Your money is genuinely less liquid than a normal ETF.

There’s also the proxy play, and it’s the one I’d actually lean toward for most people. Amazon and Alphabet between them own more than a third of Anthropic. Neither stock is anywhere close to a pure Anthropic bet — Anthropic is a rounding error against AWS or Google Cloud — but you get real, regulated, liquid exposure with no accreditation, no lockup, and no NAV premium games. If your thesis is “Anthropic wins,” owning the two hyperscalers that hold the largest outside stakes is the boring version of that trade. Boring is underrated.

What about just waiting for the IPO?

For most people this is the cleaner path, and it’s worth understanding before you chase a secondary share. Once Anthropic lists, the stock trades on a public exchange and anyone with a brokerage account can buy it — no accreditation, no $25,000 minimum, no transfer approval.

The wrinkle is the difference between buying at the IPO price and buying at the open. The IPO price is what institutional buyers and a handful of retail allocations pay before trading starts. Getting an allocation is hard for ordinary investors, though a few brokerages — Fidelity, SoFi, Robinhood, Public — have programs that occasionally hand IPO shares to retail clients, usually with eligibility hoops and no guarantee you’ll get any for a deal this hot.

Buying at the open is what most people actually do, and it means paying whatever the market sets in the first seconds of trading — frequently well above the IPO price for a name this hyped. A first-day pop feels great if you got the allocation and miserable if you bought the spike. History is mixed here: plenty of marquee tech IPOs traded below their first-day close within a year. So “wait for the IPO” doesn’t mean “buy the instant it opens.” It means you’ll have audited numbers and a real prospectus, and you can decide on a normal trading day a few weeks in.

A $965 billion sanity check

Now the part the platform ads skip. Is this a sane price?

At $965 billion on roughly $47 billion of run-rate revenue, Anthropic trades around 20x revenue — for a company that, like OpenAI and SpaceX, is still losing money. The bull case is that this is nothing like the dot-com bubble: demand is anchored by real, signed, multi-year commitments from hyperscale customers, and the revenue curve is bending up faster than almost anything in tech history. A top analyst called the filing “the opening of the floodgates” for the AI IPO market.

The bear case is just as easy to state. Three of the most valuable private companies in the world are all burning cash, the comparisons to 2000 are flying for a reason, and a 2.5x valuation jump in three months is the kind of move that tends to mean-revert. When the lockups expire and early shareholders can finally sell, supply hits the market all at once — that’s historically when high-flying IPOs wobble.

I don’t know which side is right, and neither does anyone selling you shares. What I’m confident about: paying a secondary-market premium, plus platform fees, on top of a valuation that already tripled this year, is stacking three layers of optimism. The price has to keep being generous for that to work out.

If you’re going to do it anyway

Say you’ve decided you want in. A short pre-purchase checklist I’d run through:

Confirm your accreditation status honestly before talking to any marketplace — it determines every other choice.
Get the all-in cost, not the headline price: share price, markup over the last round, platform fee, and any carry if you’re going through a fund vehicle.
Ask specifically about the lockup and the transfer-approval risk. “Available” is not “settled.”
For VCX, pull up the premium-to-NAV before buying. For ARKVX, read the redemption terms so you know when you can actually get out.
Size it as a speculative position. This is venture-style risk wearing a household-name jacket, not a core holding.

And the option nobody mentions because it doesn’t pay referral fees: wait. The S-1 will eventually go public with audited financials — actual revenue, actual losses, actual customer concentration. You’ll be able to read the real numbers instead of inferring them from funding-round press releases. Buying at the open on IPO day carries its own risk (first-day pops often fade), but at least you’ll be deciding with the full prospectus in front of you rather than a marketplace listing and a vibe.

If you’ve never bought a pre-IPO share before, the most useful thing you can do this week isn’t to wire $25,000 — it’s to open one of the marketplace listings, read the full fee disclosure, and see how you feel about the lockup terms. The valuation will still be there next month. Your capital, if you rush this, might not be.

All figures as of early June 2026 and based on reported funding-round and marketplace data — check current pricing and the official S-1 once it’s public before making any decision.

Sources: